Tobin Marcus, Wolfe Research policy and politics head, joins CNBC's 'Squawk Box' to discuss what Trump's pick for HHS ...

Fintel reports that on November 18, 2024, Wolfe Research downgraded their outlook for Matson (NYSE:MATX) from Outperform to ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...

Wolfe Research upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) to a strong-buy rating in a report ...

Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...

Wolfe Research started coverage on shares of Amgen (NASDAQ:AMGN – Free Report) in a report published on Friday, MarketBeat reports. The brokerage issued a peer perform rating on the medical research ...

Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...

Wolfe Research initiated coverage of BioMarin (BMRN) with an Outperform rating and $95 price target With limited downside risk following ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $164.99 which represents a decrease of $-4.64 or -2.74% from the prior close of $169.63. The stock opened at $169.63 and touched a ...

On Friday, Wolfe Research initiated coverage on shares of Veracyte, Inc (NASDAQ:VCYT), a diagnostics company, with an Outperform rating and a price target of $50.00. The firm highlighted Veracyte ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of AbbVie (SNSE:ABBVCL) with a Outperform recommendation. What is the Fund Sentiment? There are 4,922 funds or ...

Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic disease movement "Make America Healthy Again," championed by Robert F.